Compass Therapeutics's three largest insider shareholders as of May 30, 2026 are Advisors Llc Orbimed (Director, 15.22Mn shares), Thomas J. Schuetz (Chief Executive Officer, 6.60Mn shares), Vered Bisker-Leib (Chief Executive Officer, 3.12Mn shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Advisors Llc Orbimed | - | 0 | 15,219,994 | 10 Nov, 2022 |
| Thomas J. Schuetz | Chief Executive Officer | 6,603,336 | 0 | 10 Feb, 2026 |
| Vered Bisker-Leib | Chief Executive Officer | 3,124,426 | 0 | 09 Feb, 2024 |
| Jonathan Anderman | General Counsel | 171,000 | 0 | 05 Jan, 2026 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 08 Feb, 2026 | Thomas J. Schuetz | Common Stock | D | 36,687 | $6.52 | 6,603,336 | D | F |
| 08 Feb, 2026 | Thomas J. Schuetz | Common Stock | D | 36,687 | $6.52 | 6,603,336 | D | F |
| 09 Jan, 2026 | Thomas J. Schuetz | Common Stock | D | 46,777 | $5.35 | 6,640,023 | D | F |
| 09 Jan, 2026 | Thomas J. Schuetz | Common Stock | D | 46,777 | $5.35 | 6,640,023 | D | F |
| 02 Jan, 2026 | Richard S Lindahl | Stock Option (Right to Buy) | A | 90,000 | $0.00 | 90,000 | D | A |
| 02 Jan, 2026 | Philip Ferneau | Stock Option (Right to Buy) | A | 90,000 | $0.00 | 90,000 | D | A |
| 02 Jan, 2026 | Arjun Prasad | STOCK OPTION (RIGHT TO BUY) | A | 1,000,000 | $0.00 | 1,000,000 | D | A |
| 02 Jan, 2026 | Ellen Chiniara | Stock Option (Right to Buy) | A | 90,000 | $0.00 | 90,000 | D | A |
| 02 Jan, 2026 | Jonathan Anderman | Common Stock | A | 150,000 | $5.17 | 171,000 | D | A |
| 02 Jan, 2026 | Thomas J. Schuetz | Common Stock | A | 250,000 | $5.17 | 6,686,800 | D | A |
| 02 Jan, 2026 | Cynthia Sirard | STOCK OPTION (RIGHT TO BUY) | A | 1,000,000 | $0.00 | 1,000,000 | D | A |
| 02 Jan, 2026 | Cynthia Sirard | STOCK OPTION (RIGHT TO BUY) | A | 1,000,000 | $0.00 | 1,000,000 | D | A |
| 02 Jan, 2026 | Thomas J. Schuetz | Common Stock | A | 250,000 | $5.17 | 6,686,800 | D | A |
| 02 Jan, 2026 | James P Boylan | Stock Option (Right to Buy) | A | 90,000 | $0.00 | 90,000 | D | A |
| 02 Jan, 2026 | Arjun Prasad | STOCK OPTION (RIGHT TO BUY) | A | 1,000,000 | $0.00 | 1,000,000 | D | A |
| 02 Jan, 2026 | Philip Ferneau | Stock Option (Right to Buy) | A | 90,000 | $0.00 | 90,000 | D | A |
| 02 Jan, 2026 | Thomas J. Schuetz | Stock Option (Right to Buy) | A | 2,000,000 | $0.00 | 2,000,000 | D | A |
| 02 Jan, 2026 | Thomas J. Schuetz | Stock Option (Right to Buy) | A | 2,000,000 | $0.00 | 2,000,000 | D | A |
| 02 Jan, 2026 | Jonathan Anderman | Stock Option (Right to Buy) | A | 720,000 | $0.00 | 720,000 | D | A |
| 16 Nov, 2025 | Thomas J. Schuetz | Common Stock | D | 44,025 | $4.83 | 6,436,800 | D | F |